This is an unprecedented time. It is the dedication of healthcare workers that will lead us through this crisis. Thank you for everything you do.

      Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Salivary Gland Cancer Model for Survival +/- Postoperative Radiotherapy (PORT)

    Predicts overall survival with and without postoperative radiotherapy (PORT) for resected major salivary gland cancers.

    IMPORTANT

    This calculator has not been externally validated. Use with caution.

    When to Use

    Do you use the Salivary Gland Cancer Model for Survival +/- Postoperative Radiotherapy (PORT) and want to contribute your expertise? Join our contributor team!  

    years
    Female
    Male
    0
    1
    2
    ≥3
    1
    2
    3
    4
    0%
    0.1-10%
    10.1-49.9%
    ≥50%
    Low
    Intermediate
    High
    Negative
    Positive
    Sublingual
    Submandibular
    Parotid
    No
    Yes

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights
    Dr. Corbin D. Jacobs

    From the Creator

    Why did you develop the Salivary Gland Cancer Model?

    Salivary gland malignancies are relatively rare with extensive taxonomy and morphological diversity making them challenging to study with prospective randomized trials. To date there are no randomized data to support the use of postoperative radiotherapy (PORT) for major salivary gland malignancies, though retrospective analyses have demonstrated that PORT for locally advanced and high-risk major salivary gland cancers offers an overall survival benefit compared to no adjuvant therapy. Our primary objective was to develop and internally validate a prediction model to estimate overall survival with and without PORT for resected major salivary gland cancers.

    What pearls, pitfalls and/or tips do you have for users of the Salivary Gland Cancer Model?

    The model was developed and internally validated using the National Cancer Database (NSCD) and is subject to the inherent limitations of the data source including but not limited to coding errors, incomplete data, selection bias, and lack of locoregional recurrence. However, only subjects with completely coded demographic and pathologic data in the prognostic factors of interest were included in the creation and validation of this nomogram. This nomogram is strengthened by a large number of patients treated in a contemporary era when intensity modulated radiation therapy (IMRT) was widely available. It is also strengthened by mature median follow-up of 4.9 years for the entire population. Additionally, stringent radiotherapy thresholds were utilized to minimize underestimating the true benefit of PORT by excluding subjects who received an insufficient dose or had an excessively long radiotherapy treatment duration.

    What recommendations do you have for practitioners who utilize this Salivary Gland Cancer Model?

    I would caution practitioners to not use these results to justify omitting adjuvant therapy if there is no predicted overall survival benefit with versus without PORT. In the appropriate population, such as those with adverse features specified in NCCN guidelines, PORT may meaningfully reduce the risk of locoregional recurrence.

    How do you use the Salivary Gland Cancer Model in your own clinical practice? 

    The predicted score with the 95% confidence interval helps me more accurately counsel patients regarding their individual prognosis when they specifically request this information.

    About the Creator

    Corbin Jacobs, MD graduated from UT Southwestern with a distinction in research and subsequently completed his radiation oncology residency training at Duke University. He currently practices in Washington and Idaho as a radiation oncologist with Cancer Care Northwest.

    To view Dr. Corbin D. Jacobs's publications, visit PubMed

    Are you Dr. Corbin D. Jacobs? Send us a message to review your photo and bio, and find out how to submit Creator Insights!
    MDCalc loves calculator creators – researchers who, through intelligent and often complex methods, discover tools that describe scientific facts that can then be applied in practice. These are real scientific discoveries about the nature of the human body, which can be invaluable to physicians taking care of patients.
    About the Creator
    Dr. Corbin D. Jacobs
    Are you Dr. Corbin D. Jacobs?